# Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/ramucirumab-after-sorafenib-in-patients-with-advanced-hepatocellular-carcinoma/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Andrew X. Zhu,Yoon‐Koo Kang,Chia‐Jui Yen,Richard S. Finn,Peter R. Galle,Josep M. Llovet,Eric Assénat,Giovanni Brandi,Marc Pracht,Ho Yeong Lim,Kun‐Ming Rau,Kenta Motomura,Izumi Ohno,Philippe Merle,Bruno Daniele,Dong Bok Shin,Guido Gerken,Christophe Borg,Jean‐Baptiste Hiriart,Takuji Okusaka,Manabu Morimoto,Yanzhi Hsu,Paolo Abada,Masatoshi Kudo |
| Citations | 1,664 |
| DOI | 10.1016/s1470-2045(18)30937-9 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2908573150 |
| PMID | 30665869 |
| Type | article |
| Year | 2019 |

## Paper authors

- [Izumi Ohno](https://scholariq.org/researchers/izumi-ohno/)
- [Manabu Morimoto](https://scholariq.org/researchers/manabu-morimoto/)

## Paper journal

- [The Lancet Oncology](https://scholariq.org/journals/the-lancet-oncology/)

## Paper primary topic

- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)

## Paper topics

- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)
- [Cholangiocarcinoma and Gallbladder Cancer Studies](https://scholariq.org/topics/cholangiocarcinoma-and-gallbladder-cancer-studies/)
- [Liver Disease Diagnosis and Treatment](https://scholariq.org/topics/liver-disease-diagnosis-and-treatment/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.